<DOC>
	<DOCNO>NCT00316784</DOCNO>
	<brief_summary>The study objective eluciation dose-response function efficacy ( possibly safety ) order determine optimal dose respect efficacy safety . The study design three dose level one placebo control .</brief_summary>
	<brief_title>IDEA-033 Three Months Dose Finding OA Followed IDEA-033 Three Months Extension OA</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>clinical diagnosis OA least one knee minimum 6 month age 1875 year old eligible subject must use oral rectal NSAID least three day per week three month screen least 25 30 day screen , dissatisfied current NSAID treatment baseline visit WOMAC pain subscale least 40 mm , least 15 mm great screen visit index knee radiographic evidence consistent OA criterion grade 2 3 accord Kellgren &amp; Lawrence index knee . Radiographs mu take 6 month baseline . American College Rheumatology ( ACR ) functional class I , II III intraarticular injection arthroscopy index knee within 3 month prior screen , plan study history , physical examination radiographs suggestive rhematic disease know hypersensitivity contraindication ketoprofen ; NSAID idiosyncrasy history peptic ulcer severe liver gastrointestinal disease within last 6 month injection change oral treatment regimen glucosamine , chondroitin sulfate , hyaluronic acid , shark cartilage , vitamin E within 3 month prior screen oral parenteral corticosteroid within 3 month prior screen analgesic therapy chronic recurrent pain condition indication OA immunosuppressant within 3 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>osteoarthritis ; knee ; IDEA-033</keyword>
</DOC>